Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 714 for adult patients with refractory celiac disease type II
NL-OMON45834Phase 2Active, not recruiting
- Sponsor
- Celimmune
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in refractory celiac disease type II comparing AMG 714 with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Apr 2016; status: active, not recruiting.
02
Drugs
ordesekimab
03
Conditions
refractory celiac disease type II
Beyond the preview
Go deeper on NL-OMON45834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45834.